Polyquinoline derivatives and therapeutic use thereof

• US 8,247,396 B2
• Filed: 08/04/2006
• Issued: 08/21/2012
• Est. Priority Date: 08/04/2005
• Status: Expired due to Fees

• Current Assignee: Palumed SA, Paulmed S.A.
• Original Assignee: Centre National De La Recherche Scientifique, Palumed SA
• Inventors: Pitie, Marguerite, Boldron, Christophe, Meunier, Bernard, Deraeve, Celine
• Primary Examiner(s): Fetterolf, Brandon
• Assistant Examiner(s): Stone, Christopher R
• Application Number:
  US11/997,821
• Publication Number:
  US 20090227626A1
• Time in Patent Office: 2,209 Days
• Field of Search: 514/183
• US Class Current: 514/183
• CPC Class Codes: A61K 31/47 Quinolines; Isoquinolines
• CPC Class Codes: A61K 31/4709 Non-condensed quinolines and containing further heterocyclic rings
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07D 215/12 with substituted hydrocarbon radicals attached to ring carbon atoms
• CPC Class Codes: C07D 215/20 Oxygen atoms
• CPC Class Codes: C07D 215/38 Nitrogen atoms nitro radicals C07D215/18
• CPC Class Codes: C07D 215/40 attached in position 8
• CPC Class Codes: C07D 215/48 Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• CPC Class Codes: C07D 215/50 attached in position 4

Abstract

The invention relates to compounds of general formula (I), to the process for the preparation thereof and to the use thereof as a therapeutic agent.

Claims

1. A compound of formula (I)

2. The compound according to claim 1, selected from the group consisting of

2,2′

-(iminodimethanediyl)di(N-boc-8-quinoline amine),

2,2′

-(iminodimethanediyl)di(8-quinoline amine),

2,2′

-[(butylimino)dimethanediyl]di(N-boc-8-quinoline amine),

2,2′

-[(butylimino)dimethanediyl]di(8-quinoline amine),

N-butyl-2,2′

-imino-bis(8-quinoline amine), and

N-butyl-2,2′

-imino-bis(8-quinoline amine).

3. The compound according to claim 1, wherein X represents

NRR′

and Y represents a group of formula (IY), in which X′

represents NRR′ and

Z represents Alk-NR″

-Alk, where Alk represents a linear or branched alkyl group optionally substituted by one or more halogen atoms;

or

X represents NRR′ and

Y represents a group of formula (IY), in which X′

represents NRR′ and

Z represents NR″

;

k=1 and

R1=R2=R3=R4=R5=R1′

=R2′

=R3′

=R4′

=R5′

=H.

5. A pharmaceutical composition comprising a compound of formula (I) according to claim 1.

6. The pharmaceutical composition according to claim 5, wherein the compounds are according to claim 2.

7. The pharmaceutical composition according to claim 5, wherein the compound of formula (I) is defined as in claim 3.

4. A compound of formula (23):